Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

May 16, 2006 09:00 ET

Holmes Herbs, Inc.: Omaha Facility Nears Completion

SCOTTSDALE, ARIZONA--(CCNMatthews - May 16, 2006) - Holmes Herbs, Inc. (OTCBB:HMHB) announces that construction of its Omaha Nebraska clinical research facility is on schedule and expected to be completed later this month. The renovations include the entire building of approximately 23,000 sq. ft. and are designed to include the use of natural light, open space and an easy-to-navigate layout.

Commencing in early June, scheduled items include:

- occupy the new facility, install furnishings, medical equipment, and complete regulatory inspections;

- host grand opening, complete staffing, conduct tours and audits for pharmaceutical customers;

- commence first contract research studies.

Aggressive marketing initiatives are well underway in parallel to this schedule. Management projects that the Omaha facility will provide approximately sixteen million ($16,000,000) dollars in revenue in its first full year of operation.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information